← Eichor
Study identifier: NCT05732155 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.

Condition: Post Traumatic Stress Disorder · Moral Injury · MDMA ('Ecstasy')  ·  Sponsor: HaEmek Medical Center, Israel

PhasePhase 2
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with Post traumatic Stress Disorder and moral injury, in individual and group treatment settings. The overall safety objective is to assess the severity, incidence, and frequency of AEs, AEs of Special Interest (AESIs), and Serious Adverse Events (SAEs), concomitant medication use, suicidal ideation and behavior and vital signs .

This description comes directly from the study's public registry record.

Talk to the study team

Guy Schusheim, Dr  ·  972-4-6494138  ·  guy_sc@clalit.org.il

Gilat ron avraham, Mph  ·  972-4-6495590  ·  gilat_av@clalit.org.il

Always discuss trial participation with your own doctor first.

Locations (1)

Emek medical centerAfula, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05732155